Structure via PubChem · Public domain (PubChem)
vildagliptin
Sign in to saveAlso known as LAF237, Galvus®, LAF-237, NVP-LAF237, Xiliarx, Jalra, Galvus
Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Key facts
- Drug.synonyms
- LAF237
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 470630169
- Drug.image
- Vildagliptin.svg
- Drug.image_class
- skin-invert-image
- Drug.alt
- Skeletal formula
- Drug.image2
- Vildagliptin-3D-balls.png
- Drug.image_class2
- bg-transparent
- Drug.alt2
- Ball-and-stick model
- Drug.tradename
- Galvus, others
- Drug.pregnancy_category
- Not recommended
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- A10
- Drug.ATC_suffix
- BH02
- Drug.ATC_supplemental
- , (with metformin)
- Drug.legal_UK
- POM
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C17H25N3O2
- Molecular weight
- 303.4 g/mol
- IUPAC name
- (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
- SMILES
- C1C[C@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
- InChIKey
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N
- XLogP
- 0.9
- Polar surface area
- 76.4 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
1,478 papers- Vildagliptin.Drugs · 2006
- Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis.International journal of molecular sciences · 2020
- Vildagliptin-induced bullous pemphigoid.The New Zealand medical journal · 2021
- [Vildagliptin].Nihon rinsho. Japanese journal of clinical medicine · 2011
- Vildagliptin: a review of its use in type 2 diabetes mellitus.Drugs · 2014
via PubMed
~1 min read
Encyclopedic overview
3 sectionsContents
- Medical uses
- Adverse effects
- References
Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
The most common side effects include dizziness.
Excerpted from Wikipedia’s “vildagliptin” article, available under the CC BY-SA 4.0 licence.